Patents by Inventor Karl Henrik Johannes Ehinger

Karl Henrik Johannes Ehinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS
    Publication number: 20210401792
    Abstract: The present invention provides novel cell-permeable succinates and cell permeable precursors of succinate aimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates from mitochondrial oxidative phosphorylation, a process to which high-energy electrons are provided by the Kreb's cycle. Not all Kreb's cycle intermediates are readily permeable to the cellular membrane, one of them being succinate. The provision of the novel cell permeable succinates is envisaged to allow passage over the cellular membrane and thus the cell permeable succinates can be used to enhance mitochondrial ATP-output.
    Type: Application
    Filed: September 14, 2021
    Publication date: December 30, 2021
    Inventors: Eskil Elmer, Magnus Joakim Hansson, Karl Henrik Johannes Ehinger, Steven Moss
  • Cell-permeable succinate compounds
    Patent number: 11147789
    Abstract: The present invention provides novel cell-permeable succinates and cell permeable precursors of succinateaimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates from mitochondrial oxidative phosphorylation, a process to which high-energy electrons are provided by the Kreb's cycle. Not all Kreb's cycle intermediates are readily permeable to the cellular membrane, one of them being succinate. The provision of the novel cell permeable succinates is envisaged to allow passage over the cellular membrane and thus the cell permeable succinates can be used to enhance mitochondrial ATP-output.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: October 19, 2021
    Assignee: ABLIVA AB
    Inventors: Eskil Elmer, Magnus Joakim Hansson, Karl Henrik Johannes Ehinger, Steven Moss
  • Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation
    Patent number: 10307389
    Abstract: The present invention relates to a succinate prodrug for use in the treatment or prevention of lactic acidosis.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: June 4, 2019
    Assignee: NEUROVIVE PHARMACEUTICAL AB
    Inventors: Eskil Elmer, Magnus Joakim Hansson, Karl Henrik Johannes Ehinger, Sarah Piel, Steven Moss
  • Novel Cell-Permeable Succinate Compounds
    Publication number: 20170105961
    Abstract: The present invention provides novel cell-permeable succinates and cell permeable precursors of succinateaimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates from mitochondrial oxidative phosphorylation, a process to which high-energy electrons are provided by the Kreb's cycle. Not all Kreb's cycle intermediates are readily permeable to the cellular membrane, one of them being succinate. The provision of the novel cell permeable succinates is envisaged to allow passage over the cellular membrane and thus the cell permeable succinates can be used to enhance mitochondrial ATP-output.
    Type: Application
    Filed: April 8, 2015
    Publication date: April 20, 2017
    Inventors: Eskil Elmer, Magnus Joakim Hansson, Karl Henrik Johannes Ehinger, Steven Moss
  • Prodrugs of Succinic Acid for Increasing ATP Production
    Publication number: 20170105960
    Abstract: The present invention provides novel cell-permeable succinates and cell permeable precursors of succinate aimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates from mitochondrial oxidative phosphorylation, a process to which high-energy electrons are provided by the Kreb's cycle. Not all Kreb's cycle intermediates are readily permeable to the cellular membrane, one of them being succinate. The provision of the novel cell permeable succinates is envisaged to allow passage over the cellular membrane and thus the cell permeable succinates can be used to enhance mitochondrial ATP-output.
    Type: Application
    Filed: April 8, 2015
    Publication date: April 20, 2017
    Inventors: Eskil Elmer, Magnus Joakim Hansson, Karl Henrik Johannes Ehinger, Steven Moss
  • Succinate Prodrugs for Use in the Treatment of Lactic Acidosis or Drug-Induced Side-Effects Due to Complex I-Related Impairment of Mitochondrial Oxidative Phosphorylation
    Publication number: 20170100359
    Abstract: The present invention relates to a succinate prodrug for use in the treatment or prevention of lactic acidosis.
    Type: Application
    Filed: April 8, 2016
    Publication date: April 13, 2017
    Inventors: Eskil Elmer, Magnus Joakim Hansson, Karl Henrik Johannes Ehinger, Sarah Piel, Steven Moss
  • PROTECTED SUCCINATES FOR ENHANCING MITOCHONDRIAL ATP-PRODUCTION
    Publication number: 20150259317
    Abstract: Disclosed herein are mono or di-succinate compounds where one or both of the acid groups in the succinate core are protected in the form of biologically labile moieties, and the use of said compounds to enhance mitochondrial function. The compounds may be of formula (I) wherein R1 is H or an optionally substituted alkyl group or a group of formula (II) and R2 is independently a group according to formula (II) where formula (II) is as defined 10 herein.
    Type: Application
    Filed: October 4, 2013
    Publication date: September 17, 2015
    Applicant: Mitopharm Ltd
    Inventors: Hans Georg Fliri, Rhonan Lee Ford, David Arthur Scowen, Derek Gregory Batcheller, Karl Henrik Johannes Ehinger, Mats Eskil Elmér, Magnus Joakim Hansson, Karl Fredrik Lennart Sjövall